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This prospective, multi-center study investigated the
utility of pre-conditioning test pharmacokinetics (PK) of
intravenous busulfan (IV Bu) to optimize dosing in 204
subjects with Hodgkin (n¼64) and B-cell non-Hodgkin
lymphoma (n¼140) at 32 centers in the US and Canada. PK
studies were conducted twice during the study: test PK on
Day -14 to -11 and conﬁrmatory PK on the ﬁrst day of
conditioning, Day -8. The test PK used a 2-hour infusion of
a single IV Bu dose (0.8mg/kg) in order to determine the area
under the concentration-time curve (AUC). The test PKTable 1
AUC Exposure and Clearance from a Test Dose of 0.8 mg/kg IV Bu by Different BM
BMI Category (kg/m2)
BMI (kg/m2)
(Mean  SD)
Clearance (mL/min/
kg) Median (range)
AUC from
<1,000 m
Under Weight (<18.5) 17.9  0.51 2.76 (2.50 - 2.99) 0
Normal (18.5 - 24.9) 22.9  1.63 2.85 (1.95 - 4.39) 10 (18.5
Over Weight (25.0 - 29.9) 27.6  1.48 2.92 (2.15 - 4.11) 23 (33.8
Obese (>30.0) 35.4  5.10 3.16 (2.43 - 4.20) 35 (44.3dosing was based on adjusted ideal body weight (AIBW) for
all patients except for the subjects whose actual BW was less
than or equal to the ideal BW, where actual BW was used.
AIBW was calculated by adding 25% of the difference
between ideal BW and actual BW to ideal BW. The condi-
tioning dose of daily IV Bu was then calculated to achieve
20,000 mM*min as a total AUC. The same individualized Bu
dose was administered over 3 hours once daily from Day -8
to Day -5. If needed, dose was further adjusted on Days -6
and -5 based on conﬁrmatory PK results. VP-16 (1.4 g/m2)
was administered on Day -4, followed by 2.5 g/m2/day of
cyclophosphamide on Days -3 and -2.
Test PK from 204 subjects showed that 6 subjects (2.9%)
had higher AUC than expected (>1,500 mM*min) and 68
subjects (33.3%) had lower AUC (<1,000 mM*min). Therefore,
total AUC would have fallen outside the target range in 74
subjects (36.3%) if PK-directed dose adjustment had not been
performed. The discrepancy between expected and observed
exposure was not predicted by subject height, actual body
weight, body mass index (BMI) or body surface area. For
example, although a greater proportion of patients with high
BMI were underexposed compared with those with normal
BMI, the difference was not signiﬁcant [Table 1]. In addition,
all patients who had AUC>1,500 mM*min had normal or high
BMI. Thus, it is not possible to prospectively identify the
subpopulation which has a risk of suboptimal Bu exposure
and would gain the most beneﬁt from PK-directed dose
optimization.Hence, PK-directeddoseoptimization shouldbe
considered for all subjects when tight regulation of Bu expo-
sure is critical, and should not be limited to subpopulations.
Out of 200 patients whose conﬁrmatory PK results were
evaluable, 190 subjects (95.0%) fell within the target range
(AUC: 20,000 mM*min  20%). Eight (4.0%) and two (1.0%)
patients required dose reductions and increases, respec-
tively, for the last two days of Bu dosing. Again, no predictive
factor was identiﬁed for these patients.
In conclusion, a pre-conditioning small dose of IV Bu
estimated individual PK parameters and predicted Day-8 PK
in 95% of the subjects. This relatively large PK study identi-
ﬁed no factor that could predict outliers linked to Bu
metabolism. Therefore, when Bu exposure has to be tightly
controlled, PK-directed dose optimization should be con-
ducted for all patients.42
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Test Dose of 0.8 mg/kg (n)
Total (n)M*min 1,000-1,500 mM*min >1,500 mM*min
4 (100 %) 0 4
%) 40 (74.0%) 4 (7.4%) 54
%) 42 (62.7%) 2 (3.0%) 67
%) 44 (55.7%) 0 79
